How to manage prolonged immune effector cell-associated hematotoxicity (ICAHT) related to BCMA-directed myeloma therapy.

Authors :: Davis JA
McGann M
Marini J
Hashmi H
Source :: Expert review of anticancer therapy [Expert Rev Anticancer Ther] 2024 Jun; Vol. 24 (6), pp. 335-338. Date of Electronic Publication: 2024 Apr 21.
Publication Year :: 2024

Subjects :: Humans
Antineoplastic Agents adverse effects
Antineoplastic Agents administration & dosage
Antineoplastic Agents pharmacology
Hematologic Diseases immunology
Time Factors
Antibodies, Monoclonal administration & dosage
Antibodies, Monoclonal pharmacology
Antibodies, Monoclonal adverse effects
Multiple Myeloma drug therapy
Multiple Myeloma immunology
B-Cell Maturation Antigen immunology

Full Text Access

Tools